Object: Treatment of complex intracranial aneurysms with Pipeline embolization device (PED) (ev3/Covidien Vascular Therapies) has gained recent popularity. One application of PEDs that is not well described in the literature is the utility and long-term safety in treatment of vertebrobasilar fusiform (VBF) aneurysms. Despite the advancements in endovascular therapy, VBF aneurysms continue to challenging pathology. The authors provide long-term follow-up of VBF aneurysms treated with PEDs. Methods: We retrospectively reviewed four patients that were treated at Louisiana State University Health Sciences Center in Shreveport with PEDs for VBFs from 2012 to 2014. Each patient was discussed in a multidisciplinary setting between neurosurgeons and neurointerventionalists. Each patient underwent platelet function tests to ensure responsiveness to anti-platelet agents and was treated by one neurointerventionalist (HC). All patients were placed on aspirin and Plavix and were confirmed for therapeutic response prior to discharge. Results: Follow-up ranged from 12 to 25 months, with a mean of 14.25 months. Two cases presented with a recurrence after the initial treatment, both of which required subsequent treatment. Of the four patients treated, one patient developed hemiparesis and three died. Conclusion: Despite reports describing successful treatment of VBF aneurysms with PEDs, delayed complications after obliteration and remodeling can occur. We describe our institutional experience of VBFs treated with PEDs. Treatment of holobasilar fusiform aneurysms may carry a worse prognosis after treatment. Further long-term follow-up will provide a better understanding of this pathology.
Introduction
Treatment of complex intracranial aneurysms with Pipeline embolization device (PED) (ev3/Covidien Vascular Therapies) has gained recent popularity. One application of PEDs that is not well described in the literature is the utility and long-term safety in treatment of vertebrobasilar fusiform (VBF) aneurysms. Despite the advancements in endovascular therapy, VBF aneurysms continue to represent a challenging pathology. The anatomic aspects and large number of perforators complicate endovascular treatment of these lesions. The need for anti-platelet therapy post treatment is an additional risk factor.
The incidence of VBF aneurysms ranges from 0.06 to 5.8%. 1 Presenting symptoms of this pathology include ischemic strokes (especially of the brainstem), hydrocephalus, cranial nerve palsies, and subarachnoid hemorrhage. 1, 2 Incidence of subarachnoid hemorrhage from this disease is approximately 2.2 per 1000-person years. 3 There are several case reports and a few case series describing the use of PEDs in the treatment of VBF aneurysms. [4] [5] [6] [7] [8] [9] [10] [11] [12] There are even fewer studies with long-term follow-up and outcome. We report four cases treated with PEDs for VBF aneurysms and provide follow-up.
Center in Shreveport with PEDs for VBF aneurysms from January 2012 to January 2014. Each presenting patient was discussed in a multidisciplinary setting between neurosurgeons and neurointerventionalists. Each patient underwent platelet function tests to ensure responsiveness to anti-platelet agents. All patients were treated by one neurointerventionalist (HC) under general anesthesia. All patients were placed on anti-platelet therapy at least 5 days prior to intervention. One patient was not placed on Plavix pre-procedurally because the symptoms remained stable. All patients were treated for the fusiform aneurysm due to unresolved mass effect or persistent symptoms despite medical therapy. There was no intraprocedural anticoagulation administered since every patient was on anti-platelet therapy prior to the procedure. Every patient was placed on Aspirin 325 mg and Plavix 75 mg after the procedure. P2Y12 Plavix assay was confirmed for therapeutic response on every patient prior to discharge. Patients that showed complete obliteration of the aneurysm and resolution of their symptoms were advised to stop Plavix 6 months after the procedure. Follow-up assessment of the aneurysm was achieved with an angiogram.
Results
The average age of our study population was 62.75 years. Eighty percent of the patients were male. Follow-up ranged from 12 to 25 months with a mean of 14.25 months. The details of each case are presented in Table 1 . The average pre-operative modified Rankin Score (mRS) was 2.5 and the post-operative mRS was 5.5. We report a 25% morbidity and 75% mortality rate. An average of 4.5 PEDs was used per aneurysm and 5.25 stents per aneurysm. Two cases presented with a recurrence which required subsequent treatment (Cases 1 and 3). Case 1 presented with migration and disruption of the telescoping PED construct 25 months after initial treatment due to growth of the aneurysm. The patient stopped taking Plavix 6 months after the procedure due to complete obliteration and resolution of the symptoms. The same patient presented with ischemic insult 19 months after stopping Plavix. Case 3 had evidence of endoleak and aneurysm growth that required retreatment. Both cases which required retreatment died. Other than Case 1, all patients remained on 325 mg of aspirin and 75 mg of Plavix.
Discussion
The natural history of VBFs continues to present a moribund pathology. Despite technological advancements in surgical and endovascular technique, treatment options do not improve upon the natural history. The incidence of VBFs range from 0.6 to 5.8%, while the 5-year mortality rate ranges from 23% to 35%. 1, 13 The incidence of SAH from VBFs is 2.2/1000 person years; however, the risk of cerebral ischemia is much higher. 2 The incidence of cerebral ischemia increases from 6.1%, 17.3%, to 25.4% at 1, 5, and 10-year period, respectively. 14 There are several hypotheses which explain the pathogenesis of fusiform aneurysms. Fusiform aneurysm could be due to a congenital anomaly, arterial dissection, reticular fiber deficiency in the muscular layer, degeneration of the arterial wall due to hypertension, or mechanical injury by post-stenotic turbulence. 3, [15] [16] [17] [18] Lipid deposition in the intima and muscular layer causing atrophy may lead to tortuosity of the vessel due to increases in intraluminal pressure. Sluggish blood flow in a dilated artery may predispose the aneurysm to thrombosis development. 19 Before the advent and advancement of endovascular technology, VBF aneurysms were treated medically or surgically. With fusiform aneurysms that do not have a significant mass effect but are causing ischemia, medical management is considered the first line of treatment. If there is mass effect on neural structures with concurrent ischemic changes or if there is persistent ischemia despite anti-platelet therapy, surgical intervention may be warranted. Historically, surgical treatment consisted of three treatment options described by Drake et al: flow reduction with poor posterior collaterals via Hunterian ligation, flow reversal with adequate collaterals, trapping with mural hematoma decompression. 20 Surgical outcomes have varied widely in the literature. Kalani et al. described a series of complex vertebrobasilar aneurysms that underwent flow reduction with an overall mortality rate of approximately 45%. 21 In comparison to our mortality rate with endovascular treatment, successful treatment of this pathology continues to elude neurosurgeons.
Despite the exponential advancements in endovascular technology, VBF aneurysms continue to be one of the most formidable lesions for neurosurgeons. The first flow diverting stent commercially available, the Silk stent, was used to treat a wide range of pathology with varied success. 22 Subsequently, the PED received approval by the Food and Drug Administration in 2011.
Flow diverting stents work by reconstructing the parent artery and preventing high velocity blood flow into the aneurysm. The stagnant blood in the aneurysm sac thrombosis. This eliminates the aneurysm sac from normal circulation and decreases the risk of rupture. A second mechanism for aneurysm obliteration is that the stent mesh provides a scaffold for neointimal growth, thus isolating the aneurysm from circulation. Unfortunately, flow diverting stents present with their own set of complications when used for VBFs. With the use of stents, there is an inherent risk of thrombus development. The neointimal growth can potentially occlude perforators off the parent artery. With holobasilar fusiform aneurysms, a single stent deployment will not divert flow across the entire length of the pathology. For this reason, a telescoping construct of several stents is usually needed. This is likely to decrease the porosity of the stent and lead to complications related to perforator occlusion. Another uncertainty that lies with flow diverting stents is the use of antiplatelet agents. There is no established guidelines on the administration or combination of antiplatelet agents. In this study, all patients were placed on 81 mg aspirin and 75 mg Plavix before the procedure. After the procedure, 325 mg aspirin and 75 mg Plavix were continued indefinitely except for one patient that exhibited resolution of their preprocedural symptoms.
There is a paucity of literature describing the utility, safety, and efficacy of PEDs in the treatment of VBF aneurysms. Fiorella et al. reported the first use of PED in two patients with VBF aneurysms. 6 One patient had a combination of Multilink Vision stent (Abbott Vascular, Abbott Park, IL), Neuroform stent (Boston Scientific, Fremont, CA), and PED. The other patient had three PEDs placed. 6 After nearly a two year followup, Fiorella et al. reported one of the patients developed complete occlusion of the fusiform aneurysm and parent artery causing ischemic strokes. 23 As PEDs have gained popularity in treatment of VBF aneurysms, several reports have described their outcomes (Table 2) . 4, 5, 7, 8, 12, 13, [24] [25] [26] Several larger studies incorporate posterior circulation aneurysms of multiple locations but do not discuss VBF aneurysms as a separate entity. 5, 13, 27 Because of the paucity of literature in treatment of VBF aneurysms and PEDs, it is difficult to generalize the safety and efficacy of its use.
The largest series of VBF aneurysms is by Siddiqui et al., 10 who retrospectively reviewed 26 patients treated with PEDs. Of the 26 patients, seven were treated for fusiform vertebrobasilar aneurysms. The authors reported a 57% mortality rate with only one patient (14%) being completely asymptomatic after treatment of VBFs. Each fusiform aneurysm required an average of 4.86 PEDs, with two requiring nine PEDs. 10 Our average number of PEDs per aneurysm was almost 4 (3.8). One patient required a maximum of eight PEDs. One important finding is that patients with holobasilar aneurysms faired far worse than segmental fusiform aneurysms, with holobasilar aneurysms having a mRS of 5 or 6 in 75% of the patients.
Chalouhi et al. reported seven posterior circulation aneurysms treated with PEDs, 4 of which three were fusiform. Two out of the three patients achieved complete occlusion of the fusiform aneurysm. There were no reported complications or mortalities. The average follow-up was 5.5 months. 4 Shapiro et al. published a systematic review of VBF aneurysms. 28 Four hundred and forty cases were included in this study. Seventy percent of the patients were male, which coincides with our study (80% male). There was a 66% incidence of hypertension and 41% incidence of smoking. All of our cases had a past medical history of hypertension. The authors determined the overall mortality rate was 43% with a 7.1 year follow-up. We encountered a higher mortality rate with treatment in our case series. Shapiro et al. analyzed outcomes in subpopulations of hemorrhage, ischemic stroke, mass effect, and growth. 28 The authors discovered that patients presenting with symptoms due to mass effect or growth of aneurysm with serial imaging were poor prognostic factors. All of the patients in our case series presented due to mass effect, TIA/stroke, and refractory to medical therapy. Two of our four patients had aneurysm regrowth after treatment. We suspect an intrinsic component to a subset of VBF aneurysms that lead to a poorer outcome is likely.
Despite achieving successful PED placement and obliteration of the aneurysm, two cases presented with recurrence/growth. Krings et al. suggests partially thrombosed aneurysms repeatedly bleed into the vessel wall, 29 causing enhancement of the wall (see Figure 1(e) ). Hemorrhage into the vessel wall is also associated with adjacent brain edema. 29 With patent perforators off the aneurysm, continuous blood flow could explain the recurrence/growth we encountered in Cases 1 and 3 despite achieving radiographic obliteration of the aneurysm. To overcome this, sacrifice of the perforators off the basilar trunk would lead to catastrophic injury. If the fusiform aneurysm extends to involve the vertebral arteries, sacrifice of a vertebral artery may limit the number of patent perforators, thus possibly decreasing the risk of recurrence. This was attempted in Case 4, but immediate ischemic insult prevented the authors from observing the risk of long-term recurrence.
With treatment mortality rates after treatment higher than the reported natural history, one must question the safety of PED for VBF aneurysms. Because of the naturally long length of a holobasilar fusiform aneurysm, a telescoping construct decreases the porosity of the stents. Due to the high number of perforating branches off the basilar trunk, the chances of perforator occlusion increases, thus leading to ischemic injury. The blood supply to the perforators' and aneurysm's vasa vasorum may contribute to aneurysm regrowth, which explains aneurysm recurrence on angiography despite achieving obliteration after treatment.
One limitation of this study is the small patient population reported. This study population was performed at a single institution under a single neuroradiologist. Another limitation is although every patient presented with a holobasilar fusiform aneurysm, there is some heterogeneity in the diseases treated. Some fusiform aneurysms were localized to the basilar artery while some extended to the vertebrobasilar junction. It is unknown if Case 3 died due to complications related to treatment or natural causes, which could alter our mortality rate. There is no established protocol on the use of antiplatelet agents, which could contribute to the risk of ischemia after stent deployment.
Conclusion
The immediate risk of treating VBF aneurysms is evident in our case series. Despite reports describing successful treatment of this moribund disease process with PEDs, delayed complications after obliteration and remodeling of the aneurysm can occur. Holobasilar fusiform aneurysms may be more difficult to treat due to the length and need of a telescoping construct. Medical management in holobasilar fusiform aneurysms may lead to better outcomes than intervention. We advocate careful consideration and long-term follow-up despite successful obliteration of the VBF aneurysm.
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